Ortho Clinical Diagnostics Launches New VITROS® Anti-T. cruzi Assay

Ortho Clinical Diagnostics Launches New VITROS® Anti-T. cruzi Assay

Sep 24, 2018

Assay Is Now Available in Mexico and Countries That Accept CE Mark

RARITAN, N.J. – Ortho Clinical Diagnostics (Ortho), a global leader of in vitro diagnostics, today announced the introduction of its next-generation Anti-T. cruzi assay, with CE Mark approval and approval for use in Mexico. Ortho’s VITROS® Anti-T. cruzi assay offers best-in-class sensitivity1,2 which is key to the early detection of Chagas disease, and best-in-class specificity1,2, valued by blood banks.

“We’re committed to expanding our menu with new and innovative offerings,” said Jennifer Paine, Chief Product Portfolio and Quality, Regulatory and Compliance Officer at Ortho. “The launch of Ortho’s VITROS® Anti-T. cruzi assay will strengthen our VITROS® donor screening solution, allowing us to serve more blood banks.”

The World Health Organization (WHO) estimates that approximately 7-8 million people worldwide are infected with Trypanosoma cruzi, a blood-borne protozoan parasite that causes Chagas disease. With its incapacitating effects and mortality, this disease is one of the biggest public health problems in Latin America. Since human transmission occurs primarily through blood transfusions and organ transplants from infected donors, testing for Trypanasoma cruzi has become mandatory for blood screening in Latin America and parts of Europe.3

Ortho’s VITROS® Anti-T. cruzi assay is approved for use on the VITROS® ECi/ECiQ Immunodiagnostic System, VITROS® 3600 Immunodiagnostic Systems, VITROS® 5600 Integrated System and the  next-generation VITROS® XT 7600 Integrated System.

About Ortho’s VITROS® Systems
The VITROS® Chemistry, Immunodiagnostics and Integrated Systems from Ortho Clinical Diagnostics are a portfolio of products and patented enabling technologies which help clinical laboratories diagnose, monitor and treat disease.  VITROS® Products are engineered to help clinical laboratories with organizational, operational and economic challenges.

About Ortho Clinical Diagnostics
Ortho Clinical Diagnostics is a global leader of in vitro diagnostics serving the clinical laboratory and immunohematology communities. Across hospitals, hospital networks, blood banks and labs in more than 125 countries and territories, Ortho's high-quality products and services enable health care professionals to make better-informed treatment decisions. For the immunohematology community, Ortho's blood typing products help ensure every patient receives blood that is safe, the right type and the right unit. Ortho brings sophisticated testing technologies, automation, information management and interpretation tools to clinical laboratories around the world to help them run more efficiently and effectively and improve patient care. Ortho's purpose is to improve and save lives with diagnostics, and it does that by reimagining what's possible. This is what has defined Ortho for more than 75 years, and it's what drives Ortho forward. For more information, visit www.orthoclinicaldiagnostics.com.

1Based on a comparison of sensitivity and specificity listed in other manufacturers’ Instructions for Use
2Serological Sensitivity: 100% (95% CI 99.1% - 100%), Parasite Positive Sensitivity: 100% (95% CI 94.3% - 100%), Specificity Donor Population: 100% (CI 99.93-100%), Specificity Clinical Population: 100% (CI 98.2-100%)4
3Screening Donated Blood for Transfusion- Transmissible Infections – Recommendations, World Health Organization, 2009
4VITROS® Anti-T. cruzi (Chagas) Instructions For Use

© Ortho Clinical Diagnostics 2018

Press Contact:

Joseph Contrino
Ortho Clinical Diagnostics
1001 US Route 202
Raritan, NJ 08869 USA
T: +1 908 218 8737
joseph.contrino@orthoclinicaldiagnostics.com
www.orthoclinicaldiagnostics.com

PR-04330

${loading}